AbbVie’s promised rheumatoid arthritis blockbuster upadacitinib hits its marks in another PhIII — this time without any deaths
AbbVie $ABBV has posted another positive batch of Phase III data on its JAK1 inhibitor upadacitinib, hitting the primary and key secondary endpoints in their pivotal program for rheumatoid arthritis. And this round of data comes without any new deaths in the drug arm to rattle investors and analysts.
Their drug — formerly ABT-494 — handily outscored a placebo, which was not unexpected. The therapy barely edged out Humira on ACR 20 at 12 weeks, but did much better on a range of endpoints like ACR50 (45% versus 29%) and clinical remission rates (29% versus 18%). Only 6% of the placebo arm experienced clinical remission.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.